Recombinant P. falciparum merozoite protein-142 vaccine

Details Recombinant P. falciparum merozoite protein-142 vaccine Recombinant P. falciparum merozoite protein-142 vaccine

2007-12-11

2007-12-11

Ungar, Susan (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S272100, C424S268100, C424S265100, C424S185100, C530S300000, C530S350000, C536S023100, C536S023700, C435S069100, C435S069300

Reexamination Certificate

active

10057532

ABSTRACT:
In this application is the expression and purification of a recombinantPlasmodium falciparum(3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.

REFERENCES:
patent: 6146632 (2000-11-01), Momin et al.
patent: 6660498 (2003-12-01), Hui et al.
patent: WO9633739 (1996-10-01), None
patent: WO9730159 (1997-08-01), None
patent: WO0023105 (2000-04-01), None
patent: WO0100231 (2001-01-01), None
Kumar et al 1995, Molecular Medicine 1, 325-332.
Chang et al 1996, Infection and Immunity 64: 253-261.
Genton et al 2000, vaccine 18: 2504-2511.
Angov et al , Molecular and Biochemical Parasitology 2003, 128; 195-204.
Kashala, Vaccine 20 (2002) 2263-2277.
Tine et al , Infection and Immunity 1996, 64: 3833-3844.
Egan et al (Infection and Immunity 1995, 63: 456-466.
48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, D.C. Nov. 28-Dec. 2, 1999, Abstract 133, IDS, Sep. 30, 2003 ).
Angov et al.(1999) Process development for clinical gradePlasmodium falciparumMSPI/42(3D7) expressed inE. coli. American Journal of Tropical Medicine and Hygiene, 61 p. 207 (48th Annual Meeting of the American Society of Tropical Medician and Hygiene, Washington, D.C. Nov. 28-Dec. 2, 1999, Abstract 133).
Kumar et al. (1995) Immunogenicity and in vivo efficacy of recombinantPlasmodium falciparummerozoite surface protein -1 in Aotus monkeys. Molecular Medicine 1, 325-332.
Chang et al. (1996) A recombinant baculovirus 42-kilodalton C-terminal fragment ofPlasmodium falciparummerozoite surface protein-1 protects Aotus monkeys against malaria. Infection and Immunity 64, 253-261.

Affiliated with

Also associated with

Rating

Recombinant P. falciparum merozoite protein-142 vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant P. falciparum merozoite protein-142 vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant P. falciparum merozoite protein-142 vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3836856